Micron Biomedical, Inc. (Micron) is a biopharmaceutical company dedicated to revolutionizing the way pharmaceuticals and vaccines are administered, distributed, and stored. To reach this goal, Micron is on a rapid path to commercialize a novel vaccine and drug delivery technology, based on dissolving microneedle patches, aimed at achieving better health outcomes through enhanced therapeutic effects, simplified logistics, and improved patient compliance.
Micron’s activities leverage microneedle technology developed in the laboratory of Dr. Mark Prausnitz at the Georgia Institute of Technology (Georgia Tech), including the development of a microneedle patch for influenza vaccination that will be studied in a phase 1 clinical trial. Micron is licensing Georgia Tech’s microneedle technology to supplement its own intellectual property portfolio.
Micron is currently developing a microneedle patch for polio (IPV) vaccination to be evaluated in a phase 1 clinical trial in collaboration with the World Health Organization and the Global Polio Eradication Program with funding from the Bill & Melinda Gates Foundation. Micron is also developing a microneedle patch for influenza vaccination using internal funding. Additionally, Micron is evaluating other drugs and vaccines through undisclosed projects.
Micron was a winner of the first Innovation Challenge in support of the mission to eradicate polio globally organized by Innocentive, Inc and Beyond Polio, an initiative of the Jonas Salk Legacy Foundation and the investment firm Spencer Trask. Micron has also benefited from a Phase 1 award from the Georgia Research Alliance through VentureLab at Georgia Tech.